No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Australia’s PBAC Recommends Sandoz’s Adalimumab Biosimilar for Reimbursement Amongst other Biopharmaceuticals
On 23 August 2024, Australia’s Pharmaceutical Benefits Assessment Committee (PBAC) published the outcomes considered at its July 2024 meeting, recommending listing for one biosimilar, and three originator biopharmaceuticals. The following biosimilars were recommended...